J&J’s Baby powder tested in India and Bangladesh
pharmafile | December 21, 2018 | News story | Medical Communications | Bangladesh, Cancer, India, J&J, JJ, asbestos
Bangladeshi authorities will collect and test samples of Johnson & Johnson’s baby powders for traces of cancer causing asbestos, after a Reuter’s report revealed that the company had known it’s product had tested positive for asbestos since at least 1971.
The news comes after Indian regulators ordered J&J to stop manufacturing its Baby Powder using raw materials, in two of its Indian factories, until tests prove that the products are free of the carcinogenic contaminant.
We take this issue seriously and within a couple of days we will collect samples from the market,” S.M. Isahaque Ali, a director at the Bangladesh Standards and Testing Institution (BSTI), told Reuters.
J&J deny allegations and have described Reuters’ investigation as “one-sided, false and inflammatory”.
The company added that “All talc in India is sourced and exclusively sold in India and surrounding markets – including Sri Lanka, Bangladesh, Nepal, Bhutan, Maldives – and fully meets the regulatory standards of the Government of India.”
Louis Goss
Related Content
Geneos Therapeutics shares data from phase 1/2 trial for cancer vaccine
Geneos Therapeutics has announced that it has published positive safety, immunogenicity and efficacy data from …
Curve Therapeutics’ CSO publishes research on HIF inhibition for cancer treatment
Curve Therapeutics has announced that its chief scientific officer, Professor Ali Tavassoli has published research …
FDA approves J&J’s Opsynvi for PAH treatment
Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has …